The US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events. The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1)… Read More
Avacta Therapeutics has announced new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase Ib trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase Ia part of the study. … Read More
A landmark political agreement has been reached by the European Commission, the European Parliament and the Council of the European Union on a comprehensive reform of the EU pharmaceutical legislation. The agreement represents the most significant overhaul of the regulatory framework in over two decades and… Read More
A trade deal has been agreed between the UK and the US, which the governments says will secure and expand access to drugs, safeguard the medicines supply chain, and “drive crucial investment while supporting UK patients and industries”. The deal – part of the UK-US… Read More
Novo Nordisk has revealed that its Phase III trials of semaglutide (the active ingredient in Ozempic and Wegovy) did not demonstrate a statistically significant reduction in Alzheimer’s disease progression. The top-line results from the two-year primary analysis of evoke and evoke+ Phase III trials in early-stage symptomatic… Read More
A world-first clinical trial is launching to test an experimental vaccine designed to prevent lung cancer in people at high risk of the disease. Lung cancer remains the leading cause of cancer death in the UK, accounting for 20% of cancer deaths each year. Researchers… Read More
The US Food and Drug Administration (FDA) has laid out the process and requirements of its novel plausible mechanism pathway for personalised medicine in a New England Journal of Medicine (NEJM) editorial by Commissioner Martin Makary and Deputy Vinay Prasad. The editorial acknowledges that personalised… Read More
CRISPR Therapeutics has shared positive Phase I data from an ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3. A single-course treatment with CTX310 produced dose-dependent, durable reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum… Read More
Following a week-long bidding war with Novo Nordisk, Pfizer has acquired obesity drug specialists Metsera for $10 billion, thanks to an intervention by the US Federal Trade Commission (FTC). Metsera’s Board of Directors unanimously recommended that Metsera stockholders approve the adoption of the amended Pfizer merger agreement… Read More
Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of alpha-synuclein, a protein linked to Parkinson’s disease and related dementias. The team has successfully demonstrated it works in an animal model… Read More
iBio has announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data. The findings will be presented during an oral session at ObesityWeek 2025, taking place 4-7 November in Atlanta, USA. … Read More
In the Phase III DREAMS-3 clinical trial of mazdutide, the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist showed superior efficacy to semaglutide for body weight reduction. In Chinese patients with type 2 diabetes (T2D) and obesity, mazdutide performed better than semaglutide on the primary endpoint,… Read More
Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight people lose while taking the drug, says a new study led by University College London (UCL). The finding, the researchers say, suggests there are multiple ways the drug… Read More
Galapagos has announced its intention to wind down its cell therapy business, following a comprehensive review of strategic alternatives, including a potential divestiture. The move follows similar ones by Novo Nordisk and Takeda, which recently announced the decision to discontinue its cell… Read More
A new AI model developed by Google and Yale researchers has revealed a potential novel cancer therapy pathway. The AI model ‘Cell2Sentence-Scale 27B’ analyses single-cell RNA data using large language models and is designed to be a bridge to make single-cell data accessible, or interpretable, by AI. Read More
New gene therapy trial results have shown dramatic and sustained improvements in hearing and speech perception in children with profound genetic hearing loss. The updated data for Regeneron Pharmaceuticals’ investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were… Read More
